Sikora K, Alderson T, Nethersell A, Smedley H
Med Oncol Tumor Pharmacother. 1985;2(2):77-86. doi: 10.1007/BF02934852.
We have derived sets of human monoclonal antibodies by fusing lymphocytes from cancer patients with a human lymphoid line, LICR-LON/HMy2. Two antibodies, LGL1.1D6 and LLU6.3A4, derived from patients with glioma and bronchial carcinoma respectively, were selected for clinical study on the basis of binding patterns in radioimmunoassays with tumour cell lines and localisation of human tumour xenografts. Highly purified monoclonal antibodies were prepared using bulk supernatants from hybridomas grown in serum free medium. After radiolabelling with 131I, 1 mg antibody was injected intravenously into patients with advanced glioma and carcinoma of the bronchus. Good localisation was obtained in five out of eight patients with glioma and five out of seven patients with carcinoma of the bronchus. Despite the technical difficulties inherent in the production of human monoclonal antibodies this study demonstrates their potential for the clinical localisation of solid tumours.
我们通过将癌症患者的淋巴细胞与人类淋巴系LICR-LON/HMy2融合，获得了多组人单克隆抗体。分别从患有神经胶质瘤和支气管癌的患者身上获得的两种抗体LGL1.1D6和LLU6.3A4，基于它们与肿瘤细胞系的放射免疫分析结合模式以及人肿瘤异种移植物的定位情况，被选用于临床研究。使用在无血清培养基中生长的杂交瘤的大量上清液制备了高度纯化的单克隆抗体。用131I进行放射性标记后，将1毫克抗体静脉注射到晚期神经胶质瘤和支气管癌患者体内。在8名神经胶质瘤患者中有5名、7名支气管癌患者中有5名获得了良好的定位。尽管生产人单克隆抗体存在固有的技术困难，但这项研究证明了它们在实体瘤临床定位方面的潜力。
